AZN vs DXCM

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

DexCom, Inc. (DXCM) presents a compelling investment opportunity despite near-term price underperformance, with strong fundamentals and accelerating earnings growth driving a significant valuation disconnect. The stock trades at a forward P/E of 28.6x, below the sector average of 36.6x, while delivering robust 21.6% YoY revenue growth and 109.9% YoY earnings growth—both well above peer medians. Profitability metrics are elite, including a 30.64% ROE and 20.05% operating margin, reflecting pricing power and operational leverage in the continuous glucose monitoring (CGM) market. Although insider selling raises caution, the strong analyst consensus of 'strong_buy' and improving earnings trajectory since 2023 suggest confidence in sustained growth ahead.